COAGULATION AND FIBRINOLYSIS DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY

The purpose of this study was to measure the changes in haemostasis an d fibrinolytic parameters in the course of PTCA in patients receiving either standard medication (n = 15) (10 000 units of heparin and 250 m g of ASA) or additional therapy (n = 16) contained agent causing incre ase in fibrinolytic activity (200 mg of SP-54((R))). We found in both groups increased values of TAT, F 1+2, PAP, D-dimer, PAI-1 and t-PA. T here were no significant differences in any of the variables measured, except t-PA values obtained after vs before PTCA were significantly e levated in patients receiving SP-54((R)) (p < 0.02). Between the two g roups there were also differences in t-PA activity obtained after PTCA (p < 0.05). The additional therapy caused neither major bleeding comp lication nor ''paradoxic thrombotic incident'' as was observed in thro mbolytic therapy. To define the real impact of SP-54((R)) on haemostas is during PTCA, a randomised trial in a larger population is warranted .